当利与公共卫生相遇时:私人股权在甲治疗中的私人股权
Victor Roy1, Benjamin A Barsky2, Erin C Fuse Brown3
1Department of Family and Community Health, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19143, USA.
私募股权 (PE) 正在收购许多美沙诊所,可能会影响阿片类药物使用障碍 (OUD) 治疗的获取和质量. 需要进一步的研究,以确保金融结构支持有效的OUD护理.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 成 药物 药物 药物 药物
背景情况:
- 美国的阿片类药物过量死亡人数每年超过8万.
- 甲是阿片类药物使用障碍 (OUD) 的关键治疗方法,但获取仍然是一个挑战.
- 私募股权 (PE) 现在拥有近三分之一的阿片类药物治疗计划 (OTP).
研究的目的:
- 了解所有权结构如何影响OUD的甲治疗的获取,质量,成本和监管.
- 检查私募股权整合在OTP行业的影响.
- 确定与OUD处理中的PE所有权相关的风险和机会.
主要方法:
- 综合现有证据和监管框架的评论.
- 对影响OTP的复杂联邦监管制度的分析.
- 在不同卫生部门对PE所有权模式的审查.
主要成果:
- 在OTP中PE合并受到监管复杂性和公共融资的促进.
- 支持者声称PE可以使护理现代化,但风险包括人力不足和积极的收入优化.
- 新出现的证据表明,这可能会对护理质量和获得护理的机会产生负面影响.
结论:
- 所有权结构显著影响OUD的甲治疗.
- 需要研究和政策议程,以确保金融结构增强,而不是阻碍,公平的OUD待遇.
- 解决PE的作用对于改善阿片类药物危机中的公共卫生结果至关重要.
更多相关视频
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Drug Control Governance: Regulatory Bodies and Their Impact
Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Therapeutic Drug Monitoring: Affecting Factors
